<Page>
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 30, 2002
TRIANGLE PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
- ----------------------------- -------------------- -----------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
- -------------------------------------------------------------------- -----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
________________________________________________________________________________
(Former name or former address, if changed since last report)
<Page>
ITEM 5. OTHER EVENTS.
On August 26, 2002, Triangle Pharmaceuticals entered into a Third Amendment
to License Agreement with Bukwang Pharm. Co. Ltd., a copy of which is attached
hereto as Exhibit 10.1 and is incorporated herein by reference.
On July 30, 2002, Triangle Pharmaceuticals entered into a Termination
Agreement with Abbott Laboratories, a copy of which is attached hereto as
Exhibit 10.2 and is incorporated herein by reference.
On July 30, 2002, Triangle Pharmaceuticals entered into a Supply and
Manufacturing Agreement with Abbott Laboratories, a copy of which is attached
hereto as Exhibit 10.3 and is incorporated herein by reference.
On August 30, 2002, Triangle Pharmaceuticals entered into a Settlement and
Exclusive License Agreement with Shire Biochem Inc., Shire Pharmaceuticals Group
plc, Emory University and the University of Georgia Research Foundation, Inc., a
copy of which is attached hereto as Exhibit 10.4 and is incorporated herein by
reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits. The following documents are filed as exhibits to this Report:
+10.1 Third Amendment to License Agreement dated August 26, 2002 between
Triangle Pharmaceuticals, Inc. and Bukwang Pharm. Co. Ltd.
+10.2 Termination Agreement dated July 30, 2002 between Triangle
Pharmaceuticals, Inc. and Abbott Laboratories.
+10.3 Supply and Manufacturing Agreement dated July 30, 2002 between
Triangle Pharmaceuticals, Inc. and Abbott Laboratories.
+10.4 Settlement and Exclusive License Agreement dated August 30, 2002
between Triangle Pharmaceuticals, Inc. and Shire Biochem Inc., Shire
Pharmaceuticals Group plc, Emory University and the University of Georgia
Research Foundation, Inc.
+ Certain confidential portions of this Exhibit were omitted by means of
marking such portions with an asterisk (the "Mark"). This Exhibit has
been filed separately with the Secretary of the SEC without the Mark
pursuant to the Company's Application Requesting Confidential Treatment
under Rule 24b-2 under the Securities Exchange Act of 1934.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
---------------------------------------------
(Registrant)
September 19, 2002 /s/ Robert F. Amundsen, Jr.
- ------------------------ ---------------------------------------------
Date (Signature)
Name: Robert F. Amundsen, Jr
Title: Executive Vice President and Chief
Financial Officer